Positioning novel biologicals in CKD-mineral and bone disorders [PDF]
, 2017 Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD),
Covic, Adrian +5 more
core +1 more source
Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study [PDF]
, 2018 Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532).
Binkley +17 more
core +2 more sources
Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness [PDF]
, 2019 Breast cancer bone metastases often cause a debilitating non-curable condition with osteolytic lesions, muscle weakness and a high mortality. Current treatment comprises chemotherapy, irradiation, surgery and anti-resorptive drugs that restrict but do ...
Brandt, Diana +5 more
core +1 more source
Drug and Therapeutics Bulletin, 2021 Abstract Generic name: Romosozumab Brand name: Evenity Formulation: 105 mg solution for injection in a pre-filled pen Market Authorisation holder: UCB Pharma Limited Indication ...
openaire +3 more sources
Romosozumab: confusión respecto a sus indicaciones [PDF]
, 2023 El romosozumab es, sin duda, un excelente fármaco para el tratamiento de la osteoporosis. No obstante, su elevado precio, muy superior al de los fármacos antirresortivos, hizo que inicialmente se aceptara sin dificultad que su indicación se limitase a ...
González Macías, Jesús +1 more
core +1 more source
Romosozumab efficacy in postmenopausal women with no prior fracture who fulfill criteria for very high fracture risk [PDF]
, 2023 Objective We evaluated the efficacy of romosozumab in women from FRAME who had no prior fracture but met other criteria for very high fracture risk (VHFR).
Betah, Donald +5 more
core +1 more source
Romosozumab-associated medication-related osteonecrosis of the jaw
Oral and Maxillofacial Surgery Cases, 2023 This is the first reported case of medication-related osteonecrosis of the jaw (MRONJ) resulting from the use of romosozumab, a new anti-resorptive medication that functions through inhibition of sclerostin.
Benjamin Palla +4 more
doaj +1 more source
Osteoporosis and Sarcopenia, 2020 Objectives: Falls are the well-known risk factor for osteoporotic fractures and some medications can increase the risk of falls. Therefore, the aim of our study is to evaluate the effect of romosozumab on risk of falls in postmenopausal women.
Luis Möckel +2 more
doaj +1 more source
Denosumab versus romosozumab for postmenopausal osteoporosis treatment
Scientific Reports, 2021 Denosumab and romosozumab, a recently approved new drug, are effective and widely known molecular-targeted drugs for postmenopausal osteoporosis treatment.
Tomonori Kobayakawa +5 more
doaj +1 more source
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy : a randomised, open-label, phase 3 trial [PDF]
, 2017 Background: Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women ...
Bolognese, Michael A +21 more
core +2 more sources